Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
SynAct Pharma AB ( (SE:SYNACT) ) has provided an update.
SynAct Pharma AB announced the execution of a second conversion of 1,000,000 warrants by Heights Capital Management, generating SEK 17.7 million. This financial boost strengthens SynAct’s financial position, extending its operational runway and enhancing its appeal to potential business and development partners.
More about SynAct Pharma AB
SynAct Pharma AB is a clinical-stage biotechnology company listed on Nasdaq Stockholm, focusing on resolving inflammation through the selective activation of the melanocortin system. The company offers a range of oral and injectable selective melanocortin agonists designed to induce anti-inflammatory and inflammation resolution activity, helping patients achieve immune balance.
Average Trading Volume: 209,869
Technical Sentiment Signal: Hold
Current Market Cap: SEK947.2M
See more data about SYNACT stock on TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money